MBX Biosciences (MBX) Research & Development (2023 - 2026)

MBX Biosciences has disclosed Research & Development across 4 years of filings, most recently posting $18.5 million for Q1 2026.

• Research & Development for Q1 2026 came in at $18.5 million, down 17.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $75.2 million (up 9.39% YoY), and the FY2025 annual result was $79.2 million, up 37.87% from the prior year.
• Research & Development came in at $18.5 million for Q1 2026 at MBX Biosciences, down from $19.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $22.4 million in Q1 2025 to a low of $7.7 million in Q4 2023.
• The 4-year median for Research & Development is $16.7 million (2024), against an average of $15.6 million.
• Across the five-year window, Research & Development soared 102.78% in 2025 and retreated 17.55% in 2026, its largest moves.
• MBX Biosciences' Research & Development stood at $7.7 million in 2023, then soared by 97.01% to $15.2 million in 2024, then gained by 29.8% to $19.8 million in 2025, then dropped by 6.5% to $18.5 million in 2026.
• The last three Research & Development figures came in at $18.5 million (Q1 2026), $19.8 million (Q4 2025), and $19.3 million (Q3 2025), per Business Quant data.